Durable Responses And T-Cell Activity Highlight Potential BenefitTwo of the three patients maintained complete responses for at least eight months, with one ongoing complete response at >13 months.In addition, all three patients demonstrated persistent mKRAS-specific T cell responses.These results are particularly noteworthy as they suggest potential efficacy in a patient population that typically shows limited response to existing therapies.Company Plans Combination Study In Metastatic KRAS Pancreatic CancerSubject to funding, Elicio plans to initiate a Phase 1 study evaluating ELI-002 7P in combination with standard gemcitabine/nab-paclitaxel chemotherapy and an anti-PD-1 inhibitor in treatment-naïve metastatic mKRAS pancreatic cancer.The planned study is designed to prospectively evaluate the hypothesis generated by these observations and assess whether ELI-002 7P may enhance anti-tumor immunity and improve responsiveness to checkpoint inhibition.Data May Guide Future Development StrategyThe news comes after the company released disappointing results from its Phase 2 AMPLIFY-7P study of ELI-002 7P in patients with mutant KRAS-driven pancreatic ductal adenocarcinoma (PDAC) following standard locoregional treatment.While the trial did not achieve its pre-specified primary endpoint of disease-free survival (DFS) in the intent-to-treat population, the company pointed to early treatment benefits and subgroup findings that are shaping its planned Phase 3 program.Elicio on Wednesday said it plans to use the study findings to evaluate checkpoint inhibitor combinations further and help inform future development strategies in metastatic PDAC and the adjuvant PDAC Phase 3 trial.Analyst Consensus & Recent Actions:ELTX stock carries a Buy rating with an average price target of $21.75. Recent analyst moves include: